menu search

BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update

BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update
– Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) has now completed last patient last visit and remains on track for topline month 30 registrational data to be announced in late July 2023 – Positive results announced in Cohort 5 of Phase 2 PROPEL 2 trial of low-dose infigratinib in children […] The post BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update appeared first on ForexTV... Read More
Posted: May 4 2023, 11:30
Author Name: forextv
Views: 081833

Search within

Pages Search Results: